Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening.
Asymptomatic Infections
COVID-19
/ diagnosis
COVID-19 Nucleic Acid Testing
Calibration
Computer Simulation
Epidemics
Humans
Kinetics
Limit of Detection
Mass Screening
/ methods
Models, Theoretical
Polymerase Chain Reaction
Reproducibility of Results
Sensitivity and Specificity
Time Factors
Viral Load
Journal
Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
26
06
2020
accepted:
28
10
2020
pubmed:
22
11
2020
medline:
17
2
2021
entrez:
21
11
2020
Statut:
epublish
Résumé
The COVID-19 pandemic has created a public health crisis. Because SARS-CoV-2 can spread from individuals with presymptomatic, symptomatic, and asymptomatic infections, the reopening of societies and the control of virus spread will be facilitated by robust population screening, for which virus testing will often be central. After infection, individuals undergo a period of incubation during which viral titers are too low to detect, followed by exponential viral growth, leading to peak viral load and infectiousness and ending with declining titers and clearance. Given the pattern of viral load kinetics, we model the effectiveness of repeated population screening considering test sensitivities, frequency, and sample-to-answer reporting time. These results demonstrate that effective screening depends largely on frequency of testing and speed of reporting and is only marginally improved by high test sensitivity. We therefore conclude that screening should prioritize accessibility, frequency, and sample-to-answer time; analytical limits of detection should be secondary.
Identifiants
pubmed: 33219112
pii: sciadv.abd5393
doi: 10.1126/sciadv.abd5393
pmc: PMC7775777
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : DP5 OD028145
Pays : United States
Organisme : NIA NIH HHS
ID : F30 AG063468
Pays : United States
Organisme : NIAID NIH HHS
ID : F32 AI145112
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).
Références
Lancet. 2020 Mar 14;395(10227):e47
pubmed: 32113505
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Proc Natl Acad Sci U S A. 2020 Aug 18;117(33):19837-19843
pubmed: 32732433
Nat Commun. 2020 Sep 16;11(1):4674
pubmed: 32938924
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1059-1061
pubmed: 32342252
J Virol. 2018 Jul 31;92(16):
pubmed: 29875236
Lancet Infect Dis. 2020 Oct;20(10):1151-1160
pubmed: 32559451
Nature. 2020 Aug;584(7821):425-429
pubmed: 32604404
Nat Commun. 2021 Jan 11;12(1):267
pubmed: 33431879
Front Med (Lausanne). 2021 Mar 15;8:595773
pubmed: 33791320
Clin Infect Dis. 2021 Nov 2;73(9):e3127-e3129
pubmed: 33570097
Clin Infect Dis. 2020 Nov 19;71(16):2249-2251
pubmed: 32306036
Sci Transl Med. 2020 Aug 12;12(556):
pubmed: 32719001
Lancet. 2003 May 24;361(9371):1767-72
pubmed: 12781535
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17513-17515
pubmed: 32632012
Nat Commun. 2020 Jul 8;11(1):3496
pubmed: 32641684
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Lancet Infect Dis. 2020 Jun;20(6):656-657
pubmed: 32199493
Elife. 2020 Sep 07;9:
pubmed: 32894217
Emerg Infect Dis. 2004 Feb;10(2):256-60
pubmed: 15030693
Nat Microbiol. 2020 Oct;5(10):1299-1305
pubmed: 32651556
PLoS Comput Biol. 2017 Sep 12;13(9):e1005697
pubmed: 28898249
Nat Commun. 2020 Nov 27;11(1):6059
pubmed: 33247099
Nat Commun. 2021 Mar 12;12(1):1660
pubmed: 33712587
Lancet Microbe. 2021 Jan;2(1):e13-e22
pubmed: 33521734
Sci China Life Sci. 2020 May;63(5):706-711
pubmed: 32146694
Lancet Infect Dis. 2020 Dec;20(12):1381-1389
pubmed: 32822577
JAMA Netw Open. 2020 May 1;3(5):e2010182
pubmed: 32459353
J Vet Diagn Invest. 2011 Jan;23(1):2-15
pubmed: 21217022
J Korean Med Sci. 2020 Feb 24;35(7):e86
pubmed: 32080991
JAMA Netw Open. 2020 Jul 1;3(7):e2016818
pubmed: 32735339
Wiley Interdiscip Rev Syst Biol Med. 2011 Jul-Aug;3(4):429-45
pubmed: 21197654
Prog Mol Biol Transl Sci. 2015;129:285-326
pubmed: 25595808
N Engl J Med. 2020 May 28;382(22):2081-2090
pubmed: 32329971
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Proc Natl Acad Sci U S A. 2020 Oct 13;117(41):25904-25910
pubmed: 32973089
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
PLoS One. 2020 Dec 9;15(12):e0243597
pubmed: 33296437
Pediatrics. 2015 Feb;135(2):280-9
pubmed: 25601971
Biomol Detect Quantif. 2017 Nov 01;14:7-18
pubmed: 29255685
Lancet Infect Dis. 2020 Sep;20(9):1025-1033
pubmed: 32445710
N Engl J Med. 2020 May 28;382(22):2163-2164
pubmed: 32283004
Radiology. 2020 Aug;296(2):E115-E117
pubmed: 32073353